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Abstract
Objectives—Valproic acid and intensified antiretroviral therapy may deplete resting CD4+ T-
cell HIV infection. We tested the ability of valproic acid to deplete resting CD4+ T-cell infection
in patients receiving standard antiretroviral therapy.
Methods—Resting CD4+ T-cell infection was measured in 11 stably aviremic volunteers twice
prior to, and twice after Depakote ER 1000 mg was added to standard antiretroviral therapy.
Resting CD4+ T-cell infection frequency was measured by outgrowth assay. Low-level viremia
was quantitated by single copy plasma HIV RNA assay.
Results—A decrease in resting CD4+ T-cell infection was observed in only four of the 11
patients. Levels of immune activation and HIV-specific T-cell response were low and stable.
Valproic acid levels ranged from 26 to 96 μg/ml when measured near trough. Single copy assay
was performed in nine patients. In three patients with depletion of resting CD4+ T-cell infection
following valproic acid, single copy assay ranged from less than 1–5 copies/ml. Continuous low-
level viremia was observed in three patients with stable resting CD4+ T-cell infection (24–87, 8–
87, and 1–7 copies/ml respectively) in whom multiple samples were analyzed.
Conclusion—The prospective addition of valproic acid to stable antiretroviral therapy reduced
the frequency of resting CD4+ T-cell infection in a minority of volunteers. In patients in whom
resting CD4+ T-cell infection depletion was observed, viremia was rarely detectable by single
copy assay.
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Introduction
Despite its benefits, antiretroviral therapy (ART) cannot eliminate HIV infection [1–3]. Low
levels of HIV RNA are detected in the plasma of many patients despite ART [4–6], and can
be quantitated by a sensitive assay to limit of one copy of HIV RNA per milliliter [7].
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Another barrier to the eradication of HIV infection is the early establishment of a latently
infected pool of resting memory CD4+ cells [8–10].
Histone deacetylase (HDAC) is a critical regulator of HIV latency. The action of HDAC at
the HIV promoter maintains quiescence of HIV gene expression in infected resting CD4+
lymphocytes [11–18]. HDAC inhibition leads to HIV outgrowth from resting CD4+ T cells
of aviremic patients [19,20]. Resting CD4+ T-cell infection (RCI) was depleted when
intensified ART was given in combination with valproic acid (VPA), an anticonvulsant and
nonselective HDAC inhibitor [21]. We sought to test the ability of VPA to deplete RCI
when combined with standard ART.
Methods
HIV-infected volunteers receiving stable ARTwith plasma HIV-1 RNA less than 50 copies/
ml and a CD4 cell count of more than 300 cells/μl for at least 6 months were enrolled.
Leukapheresis was performed on two occasions prior to the addition of VPA (on day −49 to
−27 day 0), and at 12 and 16 weeks after the addition of VPA (Depakote ER 1000 once a
day). Other enrollment criteria have been described [21]; because of its interaction with
VPA, volunteers receiving zidovudine were excluded. Informed consent was obtained from
all patients.
Lymphocytes were obtained by continuous-flow leukapheresis. Isolation of resting CD4+ T
cells, recovery and quantification of replication competent virus was performed as described
[21]. Briefly, following purification resting CD4+ T cells were incubated for 2 days with the
HIV integrase inhibitor L-870812 (1 μmol/l; gift of D. Hazuda, Merck Research Laboratory,
West Point, Pennsylvania, USA) and efavirenz (15 nmol/l) or abacavir (4 μmol/l) as
determined by treatment history to insure the decay of any preintegrated HIV DNA. A total
of 93.6 million resting CD4+ T cells were plated in replicate dilutions of 2.5 million (36
cultures), 0.5 million (six cultures), and 0.1 million (six cultures) cells per well and
stimulated with 1 μg/ml PHA-L (Remel, Lanexa, Kansas, USA), a five-fold excess of
allogeneic irradiated peripheral blood mononuclear cells (PBMCs) from a seronegative
donor, and 20 U/ml interleukin (IL-2) for 24 h. Cells were then washed and fed with CD8-
depleted PBMCs collected from a selected HIV seronegative donor. These donor cells were
screened for adequate CCR5 expression, collected by leukopheresis and stored in aliquots.
Assays were performed with matched patient–donor pairs. Infected units per billion (IUPB)
were estimated as described [21]. An observed depletion of greater than 50% is significant
as this is greater than the 0.3 log10 standard deviation of our assay.
Flow cytometry analysis was performed on lymphocytes isolated at leukapheresis as
described in refs [21–24]. Cell surface phenotypes were characterized as follows: naive T
cells, CD45RA+ CD62L+; memory T cells, CD45RO+ CD45RA−; activated T cells,
HLADR+ CD38+ or HLADR+ CD69+ CD25+. CD8+ and CD4+ T cells were analyzed.
Additional studies were performed in batch on leukocytes from patients 1 to 6 preserved by
rate-controlled freezing, after thawing and overnight incubation. HIV-specific responses
were analyzed as described in ref. [24] using individual 15-mer peptides from HIV-1
consensus subtype B Nef (49 peptides), HIV-1 consensus subtype B Gag (123 peptides), and
HIV-1 consensus subtype B Pol (221 peptides) obtained from the National Institute of
Health (NIH) AIDS Research and Reference Reagent program. Baseline T-cell activation
was obtained on the media control samples. Cytokine production (IFN-γ, IL-2) was also
evaluated in the CD4+ and CD8+ T-cell populations.
Plasma HIV-1 RNA concentrations were measured by Roche Amplicor (Roche Molecular
Systems, Branch-burg, New Jersey, USA) with an assay detection limit of 50, and an ultra-
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sensitive, quantitative real-time, reverse transcriptase (RT)-PCR single copy assay (SCA)
capable of detecting and quantifying plasma HIV-1 RNA to a limit of detection of 1 copy/ml
[25]. Seminal HIV-1 RNA was measured by NucliSens QT (bioMerieux, Durham, North
Carolina, USA) with an assay detection limit of 400 copies/ml. Seminal fluid was collected
at the same time points as leukapheresis. SCA was performed on serum samples collected at
the screening visit, at 27–49 days before the start of VPA therapy, on days 0, 3, and weeks 1,
2, 4, 8, 12, and 16 after the start of VPA therapy.
Results
Twelve HIV-infected men, stably suppressed on ART, entered this study. ART included
protease inhibitors (five patients), nonnucleoside reverse transcriptase inhibitors (six
patients), or both (one patient). CD4 cell counts at entry ranged from 581 to 1121 cells/μl
(27–52%).
After determination of the frequency of resting cell infection circulating at two time points,
1000 mg VPA (Depakote ER) was administered once a day for 16 weeks. One patient was
removed from the study prior to the evaluation of VPA effect for protocol violations.
Total VPA levels were measured near trough, prior to daily dosing, and ranged from 26 to
96 μg/ml. Dose was increased if trough levels were consistently below 40 μg/ml; adjustment
to 1250 mg was required in one patient. VPA therapy was generally well tolerated. Four
patients reported minor adverse effects that resolved without specific intervention. Patient 8
reported depressive symptoms not clearly related to study drug.
CD4+ and CD8+ cells showed no changes in CD38+ HLADR+ (data not shown). In the first
six patients, studies of HIV-specific immune responses were undertaken. VPA did not alter
the proportions of naive, effector, or central memory CD4+ or CD8+ T cells (data not
shown). HIV-specific T-cell responses to viral peptide antigen were low and unaltered
following VPA therapy (data not shown).
VPA therapy combined with standard ART depleted resting cell infection in only four of the
11 patients studied (Table 1). Median VPA level at trough was not significantly different in
patients with RCI depletion (56 μg/ml) compared with those without (49 μg/ml).
Given the observation of intermittent or low-level viremia in some patients, additional
assays were performed to insure that outgrowth represented integrated provirus. After
negative selection over antibody columns, when sufficient cells were available additional
cell sorting was performed to obtain resting CD4+ populations of more than 99.9% purity in
five patients. As fewer cells (34–49 million resting CD4+ T cells) were available after
sorting, the point estimate of IUPB obtained in this assay is less precise. However, the
frequency of RCI in these highly purified cell preparations did not differ significantly from a
parallel assay performed without additional sorting (Table 2) or from the pooled results of
the standard assay (Table 1).
To measure more accurately the extent of viremia to a limit of detection of 1 copy/ml, SCA
was performed. SCA measurements correlated with Amplicor results (Table 1). In patient 9,
intermittent viremia of more than 50 copies/ml by Amplicor assay was observed. In this
patient SCA was routinely positive at 24–87 copies/ml. Therefore in this patient, results
appeared consistent with variation in PCR-based detection of stable low-level viremia, as
described in a longitudinal study [26]. In contrast, in patient 8 lack of viremia detected by
Amplicor assay early in the study was associated with viremia of less than 30 copies/ml by
SCA, whereas after week 8 clinical suspicions of nonadherence and intermittent Amplicor
assays of more than 50 copies/ml were associated with SCA of at least 68 copies/ml.
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We did not observe an association between duration of aviremia and RCI depletion. Four
patients with depletion of RCI had HIV RNA less than 50 copies/ml for a mean of 15
months (median 13, range 10–23), compared with a mean of 19 months (median 14, range
7–45) in seven patients without depletion of RCI.
An association was observed between residual or low-level viremia and the stable RCI
following VPA therapy. Depletion was not observed in patients 8 and 9, in whom
intermittent viremia was observed, nor in patient 7 who had residual viremia by SCA (Table
1). Residual viremia was rarely detectable in patients 6, 11, and 12, although only in patient
6 were we able to perform the SCA repeatedly. In contrast, viral load was repeatedly less
than 5 copies/ml in all three patients with a significant decline in RCI in whom the SCA was
performed (patients 1, 2, and 3).
In some patients, viremia may be detected in genital fluids when it is not detectable in
plasma [27]. Seminal fluid was provided by patients 1, 3, 5, 6, and 8, but HIV RNA was
undetectable (limit of detection 400 copies/ml) at all available time points.
Discussion
Current antiretroviral therapy does not eliminate persistent resting cell infection. Therapies
that selectively target the quiescent provirus and induce its expression could open new
avenues for combating persistent HIV infection.
We studied the effect of the addition of VPA to standard ARTon RCI. There was a decline
in RCI of more than 50% in four of 11 patients receiving VPA therapy combined with
standard ART. We did not observe large fluctuations or an apparent increase in resting
CD4+ T-cell infection after the addition of VPA to ART, as reported [28].
Our observations suggest that in the majority of patients on standard ART, VPA alone is not
sufficient to reduce RCI. Notably, there appeared to be an association of a decline in RCI
with the absence of low-level viremia. Jones and Perelson [29] have recently suggested that
intermittent low-level viremia to levels above approximately 7 copies/ml may prevent the
decay of chronically infected cell populations despite continuous ART. Plasma viremia was
observed to be uniformly less than 5 copies/ml in all three patients with a significant decline
of RCI in whom SCA was performed. However, SCA was less than 5 copies/ml in three
patients without a decline in RCI, although a limited number of assays were available in
these patients.
One potential result of the induction of expression of latent provirus might be the
appearance of low-level viremia in the peripheral blood, if viral expression was robust
enough to escape the tissue reservoir and appear in the peripheral circulation. We did not
observe evidence of a change in low-level viremia as measured by SCA throughout VPA
therapy, similar to the stability of low-level viremia in patients treated with ART, VPA, and
enfuvirtide [21].
Cells with an activated phenotype or HIV-specific immune cells might appear in the
peripheral blood following induction of latent provirus. However, we found the number of
these cells to be low, as is common in patients stably suppressed on ART, and without
correlation to the level of RCI after VPA therapy.
Further depletion of RCI by VPA or response to VPA in a larger subset of patients might be
observed if higher doses of VPA were administered. However, these modest findings
suggest that alternate approaches may be needed to substantially deplete RCI in the majority
of HIV-infected patients with stable suppression of viremia. If therapies that induce
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remission or eradication of HIV infection are ever achieved, they will have to be effective
over periods of treatment measured in months rather than years. Alternate approaches to
intensify ART or utilize more potent HDAC inhibitors [30,31] are in development.
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Table 1
Frequency of infection of resting CD4+ T cells from patients on standard ART alone and ART with VPA.
One single copy assayb
Patient ART IUPBc ART and VPA IUPBc
Less than 50% depletion
IUPB on VPA Range Median
1 187 90 Yes <1–1 <1
2 52 22 Yes <1–3 1
3 70 22 Yes <1–5 2
4 183 3 Yes ND ND
5 112 120 No ND –
6 54 75 No <1–1 <1
7 531 625 No 1–7 3
8 17 951 9438 Noa 8–77 25
9 4890 3300 Noa 24–87 37
10 696 1253 No <1 –
11 57 83 No <1–1 –
ART, antiretroviral therapy; IUPB, International Union of Photobiology; ND, not defined; SCA, single copy assay; VPA, valproic acid.
a
Nonconsecutive episodes of viremia of more than 50 copies during study.
b
SCA data (RNA copies/ml) represents a range from six to 10 determinations from screening visit to week 24 end-of-study visit, but for patient 10
(two assays) and 11 (three assays).
c
IUPB represents pooled data from two assays pre-VPA and two assays after addition of VPA.
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Table 2
Frequency of infection of resting CD4+ T cells.




8 8000 17 950
9 2835 2551
Variance of the sorted assay is greater than the standard assay, as fewer cells are evaluated. Frequencywas calculated after column purification
(IUPB standard assay) and column purification followed by sorting (IUPB sorted assay) at one time point while receiving ART and VPA. IUPB,
International Union of Photobiology; VPA, valproic acid.
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